• Explore /
  • Poster
  • / Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.

Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study.

Abstract Video & Slides Poster

Authors

null

Thierry Facon

Department of Hematology, Lille University Hospital, Lille, France

Thierry Facon , Philippe Moreau , Ivan Spicka , Kenshi Suzuki , Kwee Yong , Joseph Mikhael , Taro Fukao , Kamlesh Bisht , Nicole Armstrong , Sandrine Macé , Marie-Laure Risse , Thomas G. Martin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03275285

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8029)

DOI

10.1200/JCO.2023.41.16_suppl.8029

Abstract #

8029

Poster Bd #

21

Abstract Disclosures

Similar Posters

First Author: Ajay K. Nooka

First Author: Jason Westin

First Author: Philipp Harter

First Author: Dagmar Hess